Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme

By ··1 min read·3 sources

Pennsylvania Attorney General Dave Sunday sued Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark and OptumRx under the state's consumer protection law. Because Pennsylvania has no general antitrust statute, the case relies on deception claims rather than price-fixing law.

The Pennsylvania Office of Attorney General's Antitrust Section filed a complaint on October 9, 2026, in the Commonwealth Court of Pennsylvania against the three largest insulin manufacturers, Eli Lilly and Company, Novo Nordisk Inc. and Sanofi-Aventis U.S. LLC, and the three largest pharmacy benefit managers, Express Scripts, CVS Caremark and OptumRx, along with affiliated entities. Attorney General Dave Sunday announced the suit on October 13.

The complaint describes an "Insulin Pricing Scheme" in which manufacturers allegedly raised list prices and paid rebates and fees to PBMs, calculated as a percentage of list price, in exchange for preferred formulary placement. It alleges that diabetes drugs costing under $2 to make rose from about $20 to between $300 and $700, an increase of more than 1,000%, and that PBMs misrepresented their savings and the purpose of their formularies.

The claims arise under the Unfair Trade Practices and Consumer Protection Law, with unjust enrichment and civil conspiracy counts. The state seeks restitution, injunctive relief and civil penalties of $1,000 per violation, or $3,000 where the victim is 60 or older. No defendant responses were reported.

The legal route matters. Pennsylvania is the only state without a general antitrust statute, and the Commonwealth Court held in 2019 that a market-allocation claim was not viable under the consumer protection law, while allowing deception claims to proceed. The case therefore pairs a competition theory with deception allegations.

Pennsylvania joins a long list of states pursuing the same theory, including Missouri, Oregon and Iowa in January 2026. It follows the FTC's settlements with Express Scripts in February and Caremark in July, and OptumRx's proposed settlement in June. The first two carried no monetary penalty; Optum's terms have not been disclosed. Philadelphia District Attorney Larry Krasner filed a similar suit against a nearly identical group of defendants in 2024.

Sources

  1. duanemorris.com · duanemorris.com/alerts/pennsylvania_attorney_general_sues_insulin_manufacturers_pbms_testi…
  2. phillyvoice.com · phillyvoice.com/insulin-prices-pennsylvania-lawsuit-pharmaceutical-companies
  3. newsfromthestates.com · newsfromthestates.com/node/432834

Cite this report

The Precedent. "Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme." October 15, 2026. https://theprecedent.org/article/pennsylvania-sues-the-three-largest-insulin-makers-and-pbms-over-alleged-pricing